Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Neupro Clear all

Conditions: Idiopathic Parkinson's Disease
Interventions: apomorphine infusion; Drug
Lead sponsor: MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more

Conditions: Parkinson's Disease
Interventions: LY03003, Neupro; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Long Beach, California • Orlando, Florida • Douglasville, Georgia + 2 more

Conditions: Parkinson's Disease
Interventions: ROTIGOTINE; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Long Beach, California • Hallandale, Florida • Atlanta, Georgia

Conditions: Restless Legs Syndrome, End-Stage Renal Disease
Interventions: Rotigotine, Placebo; Drug
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Brandon, Florida • Newton, Massachusetts • West Seneca, New York + 3 more

Conditions: Anxiety Disorders, Parkinson Disease
Interventions: rotigotine transdermal patch, placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 89 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parkinson's Disease
Interventions: Rotigotine; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 31 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 37
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 34 more

Conditions: Restless Legs Syndrome
Interventions: Rotigotine, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more

Conditions: Parkinson´s Disease
Interventions: Kinesia-ONE™, Kinesia-360™, Rotigotine; Device · Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 8
States / cities: Fountain Valley, California • Boca Raton, Florida • Winfield, Illinois + 5 more

Conditions: Idiopathic Parkinson's Disease
Interventions: Rotigotine; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 31 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 9
States / cities: Birmingham, Alabama • St. Petersburg, Florida • Fort Wayne, Indiana + 6 more

Conditions: Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description); Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Parkinson's Disease
Interventions: Rotigotine, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: Reseda, California • Ventura, California • St. Petersburg, Florida + 4 more

Conditions: Post-op Pain
Interventions: Neupro® transdermal patch/placebo; Drug
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Parkinson Disease
Interventions: LY03003, Neupro 4Mg/24Hr Transdermal Patch; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease
Interventions: Rotigotine; Drug
Lead sponsor: John Winkelman, MD, PhD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch
Interventions: Rotigotine Transdermal System; Drug
Lead sponsor: Inflamax Research Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Parkinson Disease
Interventions: LY03003; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Hallandale, Florida • Atlanta, Georgia

Conditions: Restless Legs Syndrome
Interventions: Rotigotine 1 milligram/24 hours, Rotigotine 2 milligram/24 hours, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Culver City, California

Conditions: Advanced Parkinson's Disease
Interventions: Rotigotine, Placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 30 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 26
States / cities: Birmingham, Alabama • Gilbert, Arizona • Fountain Valley, California + 23 more

Conditions: Parkinson's Disease
Interventions: Rotigotine; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: St. Petersburg, Florida • Salisbury, North Carolina

Conditions: Restless Legs Syndrome
Interventions: buprenorphine transdermal delivery system (BTDS), Placebo for BTDS patch; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Early-Stage Parkinson's Disease
Interventions: Rotigotine; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 31 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 37
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Restless Legs Syndrome
Interventions: Rotigotine 1 mg/24 h, Rotigotine 2 mg/24 h, Rotigotine 3 mg/24 h; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Culver City, California

Conditions: Restless Legs Syndrome
Interventions: Rotigotine; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 9 more

Conditions: Restless Legs Syndrome
Interventions: Rotigotine; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Spring Hill, Florida + 2 more

Search by objective public record fields.

Infusion of Apomorphine: Long-term Safety Study

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Quality Improvement and Practice Based Research in Neurology Using the EMR

Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

Switching From Oral Dopamine Agonists to Rotigotine

Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Butrans for Treatment of Restless Legs Syndrome

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome